Fexofenadine for Itching in Allergic Reactions

Indications and Efficacy

The American Academy of Allergy, Asthma, and Immunology recommends fexofenadine, a second-generation antihistamine, for relief of symptoms associated with seasonal allergic rhinitis, including itchy nose, palate, throat, and itchy/watery/red eyes, due to its non-sedating properties and efficacy in reducing symptoms 1, 2

Fexofenadine is a second-generation antihistamine that does not cause sedation at recommended doses, unlike first-generation antihistamines which have significant potential to cause sedation, performance impairment, and anticholinergic effects, as supported by the Journal of Allergy and Clinical Immunology 1, 2
Even at higher than FDA-approved doses, fexofenadine maintains its non-sedating properties, unlike loratadine and desloratadine which may cause sedation at higher doses, according to the Journal of Allergy and Clinical Immunology 2, 3

For generalized pruritus of unknown origin (GPUO), nonsedative antihistamines such as fexofenadine 180 mg should be considered before sedative antihistamines, as recommended by the British Journal of Dermatology 4, 5
For pruritus associated with EGFR inhibitor therapy (common in cancer treatment), oral H1-antihistamines such as fexofenadine may provide relief for patients with grade 2/3 pruritus, according to the Annals of Oncology 6, 7
For allergic rhinitis with itching symptoms, second-generation antihistamines like fexofenadine are generally preferred over first-generation antihistamines, as supported by the Journal of Allergy and Clinical Immunology 1, 8

While effective for itching, fexofenadine has limited effect on nasal congestion in allergic rhinitis, as noted by the Journal of Allergy and Clinical Immunology 8
In elderly patients, nonsedating antihistamines like fexofenadine are particularly preferred due to the increased sensitivity of older adults to the psychomotor impairment and anticholinergic effects of first-generation antihistamines, according to the Journal of Allergy and Clinical Immunology 2

Fexofenadine, loratadine, and desloratadine do not cause sedation at recommended doses, while cetirizine and intranasal azelastine may cause sedation at recommended doses, as reported by the Journal of Allergy and Clinical Immunology 1, 2
Among the newer, nonsedating antihistamines, no single agent has been conclusively found to achieve superior overall response rates, according to the Journal of Allergy and Clinical Immunology 1

Fexofenadine, loratadine, and desloratadine do not cause sedation at recommended doses, making them preferable options for school-aged children 9, 10
Cetirizine may cause mild drowsiness (13.7% compared to 6.3% with placebo) at standard doses, which could potentially affect school performance 11, 10
Intranasal azelastine has been associated with sedative properties and bitter taste, with 11.5% of patients reporting somnolence in clinical trials 10

Among second-generation antihistamines, no single agent has been conclusively shown to have superior overall efficacy for allergic rhinitis symptoms 10, 12

The American Academy of Allergy, Asthma, and Immunology recommends fexofenadine as the first choice for allergic rhinitis in children due to its non-sedating properties and favorable safety profile 9, 13
Loratadine is an alternative option, with non-sedating properties at recommended doses 9, 12
Cetirizine may be considered if other options are ineffective, but may cause mild drowsiness that could affect school performance 10, 11

Second-generation antihistamines are generally preferred over first-generation antihistamines due to significantly less sedation and cognitive impairment 12
Patients with low body mass for their age may be at higher risk for sedation even with standard doses of loratadine or desloratadine 11

Avoid first-generation antihistamines (diphenhydramine, chlorpheniramine) in school-aged children due to significant sedation and cognitive impairment that may affect school performance 13, 12
Avoid combination products with decongestants in children under 12 years without careful consideration of risks and benefits 11, 12